应对耐药真菌挑战的新型药物与靶点
Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.
PubMed 文献 · J Infect Dis · 2017-01-01
耐药真菌的出现对人类健康构成重大威胁,免疫受损患者的耐药真菌感染仍导致显著发病和死亡。本文综述了广谱抗真菌药物研发面临的挑战,并重点介绍了可扩展耐药侵袭性真菌感染治疗手段的新型药物靶点。
要点
- 耐药真菌感染在免疫受损患者中发病率和死亡率高,亟需新型抗真菌药。
- 广谱抗真菌药物的研发面临挑战,需探索新靶点。
- 新型靶点有望扩充治疗耐药侵袭性真菌感染的药物库。
核心结论
- 耐药真菌感染威胁人类健康,尤其在免疫受损患者中导致显著发病和死亡,亟需新抗真菌药。
主要发现
- 耐药真菌感染在免疫受损患者中持续造成显著发病和死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The emergence of drug-resistant fungi poses a major threat to human health. Despite advances in preventive, diagnostic, and therapeutic interventions, resistant fungal infections continue to cause significant morbidity and mortality in patients with compromised immunity, underscoring the urgent need for new antifungal agents. In this article, we review the challenges associated with identifying broad-spectrum antifungal drugs and highlight novel targets that could enhance the armamentarium of agents available to treat drug-resistant invasive fungal infections.
来源:J Infect Dis,查看原文。版权归原作者所有。
引用
- McCarthy MW, Kontoyiannis DP, Cornely OA, et al. Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. J Infect Dis. 2017. PMID: 28911042. doi:10.1093/infdis/jix130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。